Synonym
Haloperidol hemisuccinate
IUPAC/Chemical Name
Butanedioic acid, mono(4-(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-4-piperidinyl) ester
InChi Key
MRYKQXMLMOCFBB-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H27ClFNO5/c26-20-7-5-19(6-8-20)25(33-24(32)12-11-23(30)31)13-16-28(17-14-25)15-1-2-22(29)18-3-9-21(27)10-4-18/h3-10H,1-2,11-17H2,(H,30,31)
SMILES Code
OC(=O)CCC(=O)OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c3ccc(Cl)cc3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
|
Solvent |
mg/mL |
mM |
| Solubility |
| To be determined |
0.0 |
0.00 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
475.94
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Jann MW, Penzak SR. Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents. CNS Drugs. 2018 Mar;32(3):241-257. doi: 10.1007/s40263-018-0508-6. Review. Erratum in: CNS Drugs. 2018 Jun 2;:. PubMed PMID: 29569082.
2: Geerts H, Spiros A, Roberts P, Alphs L. A quantitative systems pharmacology study on optimal scenarios for switching to paliperidone palmitate once-monthly. Schizophr Res. 2018 Jan 25. pii: S0920-9964(17)30711-9. doi: 10.1016/j.schres.2017.11.016. [Epub ahead of print] PubMed PMID: 29395607.
3: Emsley R, Parellada E, Bioque M, Herrera B, Hernando T, García-Dorado M. Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders: a systematic review of randomized and nonrandomized studies. Int Clin Psychopharmacol. 2018 Jan;33(1):15-33. doi: 10.1097/YIC.0000000000000195. PubMed PMID: 28817397.
4: Dekkers BGJ, Eck RJ, Ter Maaten JC, Touw DJ. An acute oral intoxication with haloperidol decanoate. Am J Emerg Med. 2017 Sep;35(9):1387.e1-1387.e2. doi: 10.1016/j.ajem.2017.07.013. Epub 2017 Jul 5. PubMed PMID: 28705742.
5: Decuypere F, Sermon J, Geerts P, Denee TR, De Vos C, Malfait B, Lamotte M, Mulder CL. Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study. PLoS One. 2017 Jun 14;12(6):e0179049. doi: 10.1371/journal.pone.0179049. eCollection 2017. PubMed PMID: 28614404; PubMed Central PMCID: PMC5470699.
